|
|
 |
|
|
|
|
[Defense industry] |
|
|
|
|
|
|
|
|
work breakdown structure, 86, 87 |
|
|
|
|
|
|
|
|
project management in, 82-100 |
|
|
|
|
|
|
|
|
Defining the project target (in project planning), 53-57 |
|
|
|
|
|
|
|
|
Drug delivery devices |
|
|
|
|
|
|
|
|
the changing device business, 188, 189 |
|
|
|
|
|
|
|
|
development of, 187-201 |
|
|
|
|
|
|
|
|
documentation, 200 |
|
|
|
|
|
|
|
|
key tools for device development, 198-200 |
|
|
|
|
|
|
|
|
design review, 199, 200 |
|
|
|
|
|
|
|
|
failure modes and effects analysis, 199 |
|
|
|
|
|
|
|
|
project plan, 198, 199 |
|
|
|
|
|
|
|
|
technical tools, 200 |
|
|
|
|
|
|
|
|
makeup of the project team, 192, 193 |
|
|
|
|
|
|
|
|
management of diverse project resources, 192 |
|
|
|
|
|
|
|
|
meeting customers' needs, 194-196 |
|
|
|
|
|
|
|
|
phasing the project, 193, 194 |
|
|
|
|
|
|
|
|
product requirement specification, 196, 197 |
|
|
|
|
|
|
|
|
reasons for drug delivery, 188 |
|
|
|
|
|
|
|
|
selecting a development resource, 188-192 |
|
|
|
|
|
|
|
|
testing, 197, 198 |
|
|
|
|
|
|
|
|
Drug development strategy, 2-20 |
|
|
|
|
|
|
|
|
development risk management, 21 |
|
|
|
|
|
|
|
|
early strategy, 3-14 |
|
|
|
|
|
|
|
|
back-up and follow-up strategy, 11-14 |
|
|
|
|
|
|
|
|
improving input quality, 3, 4 |
|
|
|
|
|
|
|
|
product profile, 4-6 |
|
|
|
|
|
|
|
|
profile of a target product (PRIONIX), 6-10 |
|
|
|
|
|
|
|
|
[Drug development strategy] |
|
|
|
|
|
|
|
|
selection criterion for further development, 10, 11 |
|
|
|
|
|
|
|
|
future visions of, 273-277 |
|
|
|
|
|
|
|
|
projects as investment opportunities, 20 |
|
|
|
|
|
|
|
|
registration and life-cycle development, 14-26 |
|
|
|
|
|
|
|
|
health economics strategy, 14-17 |
|
|
|
|
|
|
|
|
life-cycle strategy, 19, 20 |
|
|
|
|
|
|
|
|
postfiling and launch strategy, 18, 19 |
|
|
|
|
|
|
|
|
registration and launch strategy, 17, 18 |
|
|
|
|
|
|
|
|
Electronic mail (E-mail) |
|
|
|
|
|
|
|
|
impact on the working environment of, 265 |
|
|
|
|
|
|
|
|
Failure modes and effects analysis (FMEA), 199 |
|
|
|
|
|
|
|
|
Future visions of drug development, 273-277 |
|
|
|
|
|
|
|
|
cross-functional high-performance teams, 273-275 |
|
|
|
|
|
|
|
|
globalization, 273, 275, 276 |
|
|
|
|
|
|
|
|
pharmaceutical project management, 277-282 |
|
|
|
|
|
|
|
|
virtual organization, 273, 276, 277 |
|
|
|
|
|
|
|
|
Genomics, 22 |
|
|
|
|
|
|
|
|
Globalization, 273, 275, 276 |
|
|
|
|
|
|
|
|
clinical research in the global village, 224-231 |
|
|
|
|
|
|
|
|
automating progress control, 226, 227 |
|
|
|
|
|
|
|
|
building tighter controls, 227, 228 |
|
|
|
|
|
|
|
|
cautious approach, 225 |
|
|
|
|
|